Kidney damage in COVID-19 patients with or without chronic kidney disease: Analysis of clinical characteristics and related risk factors by Liu, Hong et al.
Indian Journal of Experimental Biology 
Vol. 58, November 2020, pp. 811-817 
Kidney damage in COVID-19 patients with or 
without chronic kidney disease: Analysis of 






















1Department of Nephrology; 2Department of Pediatrics, 
Wuhan No. 1 Hospital, Wuhan, China 
Received 12 October 2020; revised 24 October 2020 
COVID-19 poses more risk to patients who already suffer from 
other diseases, particularly respiratory disorder. In this study, we 
analyzed the clinical characteristics and related risk factors during 
hospitalization of COVID-19 patients admitted with kidney 
damage. A total of 102 COVID-19 patients with kidney damage 
[irrespective of their chronic kidney disease (CKD) history] during 
hospitalization were included in this study. The patients were 
divided into a core group and a group who developed critical illness 
or death. Clinical data included age, gender, length of 
hospitalization, clinical manifestations, medical history, 
hypersensitive C-reactive protein (hs -CRP), high serum creatinine, 
low cardiac troponin I (cTnI), and hemoglobin. Univariate and 
multivariate logistic regression models were used to analyze the risk 
factors of patients' outcome. Among the outcomes, 75 patients 
(73.53%) were cured, 27 (26.47%) developed to critical illness or 
death, 20 (19.61%) of them died. A total of 36 (4.26%) out of 845 
COVID-19 patients, developed acute kidney injury (AKI). 
Decreased oxygen saturation, elevated hs-CRP, elevated serum 
creatinine, elevated cTnI, and anemia were related factors for 
COVID-19 patients who developed to critical illness or death 
(P <0.05). Decreased oxygen saturation, elevated hs-CRP and 
anemia were not independent factors, but elevated serum creatinine 
and elevated cTnI were independent factors for COVID-19 patients 
who developed to critical illness or death (P <0.05). Among 
COVID-19 patients with or without CKD but with kidney damage 
during hospitalization, patients with elevated serum creatinine and 
elevated TnI, more likely to developed critical illness or death. 
Keywords: Acute kidney injury (AKI), Anemia, CKD, 
Hypersensitive C-reactive protein, Serum creatinine, Cardiac 
troponin I 
Since December 2019, an outbreak of novel 
coronavirus pneumonia (Coronavirus disease 2019, 
COVID-19) has developed into a global pandemic
which has been declared by the World Health 
Organization on March 11, 2020
1
. COVID-19 is 
caused by a novel, enveloped single-stranded RNA 
virus, and is the 7
th
 known coronavirus in humans and 
belongs to the same phylogenetic family as the 2002 
SARS and the 2012 MERS-CoV-2
2
. Coronaviruses 
can be divided into four genera: α, β, γ and δ. There 
are six coronaviruses that cause disease in humans, 
including 229E and NL63 of the α-genus and OC43, 
HKU1, SARS-CoV and MERS-CoV of the β genus, 
however, the human coronavirus infection is mainly 
related to the respiratory, intestinal and nervous 
systems
3
. The SARS‐CoV‐2 possesses high 
pathogenicity and transmissibility, hence, has challenged 
the global healthcare system
4
.  
While containment and mitigation measures have 
intensified across the world, and various 
pharmacologic compounds are being tested to work 
against the deadly COVID-19, however, lack of 
information has made the task more intricate
2
. 
However, various epidemiological studies carried out 
in past helps in understanding transmission dynamics, 
mortality trends and various models that may provide 
subsequent measures to control virus transmission
5
. 
Furthermore, epidemiological data helps in 
identification of predictive factors, risk stratification, 
management of hospital resource and guide public 
health experts
6
. Along with epidemiological history, 
clinical features and pathogen detection methods are 
important in the diagnosis of COVID‐19. Timely and 




There are reports on hospitalization of COVID-19 
patients with comorbid conditions such as CVD, 
hypertension, CKD, diabetes mellitus (DM), etc. and 
their impact on the disease outcomes when compared 
to patients with subclinical or mild symptoms of 
COVID-19. A pooling data from six studies (n=1527) 
revealed that prevalence rates of hypertension, CVD, 
and DM of 17.1, 16.4 and 9.7%, respectively, in 
COVID-19 patients
7
. It has been seen that patients 
with COVID-19 disease with comorbidities such as 
hypertension or DM, are more likely to develop a 
more severe course and progression of the COVID-19 
disease, and such patients should take all necessary 
precautions to avoid getting infected
8
. A meta analysis 
of available data has shown CKD seems to be 
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associated with enhanced risk of severe COVID-19 
infection, and shall be regarded as an important factor 
in future risk stratification models for COVID-19
6
. 
Among CKD patients, the markedly altered immune 
system and immuno-suppressed condition may 
predispose them to COVID-19 infection. Published 
data shows that risk for severe COVID-19 is 3-fold 
higher in CKD patients CVD
9
. 
By early May, 2020, COVID-19 showed >4 
million confirmed cases and 0.33 million fatalities 
from 214 countries with US in lead. People with 
respiratory disorders were more susceptible to 
COVID-19 who suffered multiple organ failure
1
. The 
clinical manifestations and prognosis of different 
individuals after COVID-19 infection varied greatly. 
Studies have shown that patients with chronic kidney 
disease (CKD) have a worse prognosis after infection 
with COVID-19
10
 and the mortality rate of COVID-
19 patients with acute kidney injury (AKI) was 
extremely high
11,12
. At present, there are few studies 
on the clinical outcome and prognosis of COVID-19 
patients of kidney damage with or without CKD.  In 
the present study, we retrospectively analyzed the 
general condition of COVID-19 patients with kidney 
damage with or without CKD and the risk factors 
developing into critical illness or deathand thereby 
provide reference for the prognosis judgment  
and clinical treatment of COVID-19 patients with 
kidney damage. 
 
Materials and Methods 
 
Study design and participants 
Data for this single-center, retrospective, 
observational study was obtained from the electronic 
medical records of HIS system of Wuhan No. 1 
Hospital. A total of 845 patients were infected with 
SARS-CoV-2, among them 107 cases had kidney 
damage but with or without CKD during 
hospitalization from December 31, 2019 to March 20, 
2020. Among all, 5 patients with incomplete 
laboratory data were excluded from the study. 
Statistical analysis was performed on the clinical data 
of 102 patients,and according to the outcome, the 
patients were divided into a cure group and a group of 
patients who developed critical illness or death.  
The study was approved by the Institutional Ethics 
Board of Wuhan No.1 Hospital [No. (2020) 8]. 
Although the retrospective study was exempted from 
written informed consent, however, verbal consent 
obtained from all patients included in the study. 
Diagnostic criteria 
According to the New Coronavirus Pneumonia 
Diagnosis and Treatment Program (Trial Version 7) 
issued by the National Health Commission of the 




(i) Patients who had history of travel or residence 
in Wuhan and surrounding areas or other communities 
with reported cases within 14 days before the onset; 
(ii) Had a history of contact with COVID-19 patients 
(positive nucleic acid test) within 14 days before 
onset; (iii) Had contacted patients with fever or 
respiratory symptoms from Wuhan and surrounding 
areas, or from communities with case reports within 
14 days before onset; and (iv) Patients who are from 
clusters of disease;  
 
Clinical manifestations 
(i) Fever and/or respiratory symptoms; (ii) 
Pneumonia manifestations of COVID-19 in radiologic 
imaging; and (iii) Whether the total number of white 
blood cells/ lymphocyte was normal or decreased in 
the early stage of onset;  
 
Etiology or serology 
(i) Real-time fluorescent RT-PCR detects the 
positive nucleic acid of the COVID-19 coronavirus; 
(ii) Sequencing of viral genes, highly homologous to 
the known COVID-19 coronavirus; and (iii) Positive 
for serum novel coronavirus-specific IgM antibody 
and IgG antibody, or serum novel coronavirus-
specific IgG antibody changed from negative to 
positive or the recovery period was 4 times or more 
higher than the acute period.  
 
Suspected cases 
In case of clear or non-clear epidemiological 
evidences, two and three clinical manifestations must 
be met, respectively. A suspected case with one of the 
etiological or serological evidence can be diagnosed 
easily for the disease. In this study, clinical outcome 
endpoint was monitored up to May 5, 2020.  
 
Clinical classification 
As per the established guidelines, the following 
criteria must be met to decide whether the case is 
mild, moderate, severe or critical type: Mild type: 
Patients with mild clinical symptoms but with no viral 
pneumonia manifestations on chest CT scans; 
Moderate type: Patients with fever, respiratory tract 
infections, other symptoms and have pneumonia 
manifestations on chest CT scans; Severe type: 
Patients with shortness of breath, respiratory rate 




(RR) >30 breaths/min, oxygen saturation <93% at rest 
state, arterial blood oxygen partial pressure 
(PaO2)/oxygen concentration (FiO2) ≤300 mmHg  
(1.0 mmHg = 0.133 kPa). At high altitude (over 1000 
meters above sea level), PaO2/FiO2 should be 
corrected according to the following formula:  
 
Furthermore, pulmonary lesion progression >50% 
within 24–48 h on radiologic imaging were treated as 
severe cases. Critical type: Patients with episodes of 
respiratory failure requiring mechanical ventilation, 
presence of shock, and other organ failure that 
requires monitoring and treatment in the intensive 
care unit are treated as critical type.  
As per established guidelines, CKD includes 
kidney damage or glomerular filtration rate of  
<60 mL/min/1.73 m
2
, time >3 months. Besides, it 
includes abnormal kidney pathology or abnormal 
kidney damage markers in blood and urine and 
abnormal renal imaging examination. While as AKI 
has a diagnostic criteria of the 2012 KDIGO (Kidney 
Disease Global Outcomes) guidelines which includes: 
Blood creatinine increased by more than 26.5 μmol/L 
(0.3 mg/dL) within 48 h, increased blood creatinine > 
1.5 times of the baseline, confirmed or speculated 
within 7 days; and urine output of <0.5 mL/(kg·h) for 
more than 6 h. Thus, a patient is diagnosed with AKI 
if one of the three above guidelines is met. 
 
Data collection 
Clinical data was retrospectively collected through 
the electronic medical record HIS system of Wuhan 
No. 1 Hospital, which includes age, gender, length of 
hospitalization, clinical manifestations, past medical 
history and laboratory examination results during 
hospitalization, such as value of hs -CRP, serum 
creatinine, cTnI and hemoglobin. 
 
Statistical analysis 
SPSS24.0 software was used for statistical 
description and analysis of the data. The measurement 
data conforming to the normal distribution was 
expressed by , and the independent sample t-test 
was used for comparison between groups. The 
measurement data of non-normal distribution was 
represented by the median M (P25, P75), and Mann-
Whitney U-test was used for comparison between 
groups. Count data was expressed in frequency (%), 
and Pearson chi-square test was used for comparison 
between groups. Univariate and multivariate logistic 
regression analysis was used to analyze the related 
factors of the 102 patients with COVID-19 outcomes 
(critical illness or death). The P <0.05 was considered 
statistically significant. 
 
Results and Discussion 
 
General situation 
A total of 845 patients were diagnosed and were 
found to be infected with SARS-CoV-2, among them 
91 patients had CKD while as 16 patients were non-
CKD but had kidney damage during hospitalization. 
In 107 cases, 5 patients with incomplete laboratory 
data were excluded from the study. The statistical 
analysis outcomes for clinical data of 102 patients are 
presented by Fig. 1.  
The median age of the 102 patients was 73.5 years 
(61 males and 41 females) with an average hospital 
stay of 25.74 days. Among them, 72 patients had 
hypertension (70.59%), 29 patients had diabetes 
(28.43%), 26 patients had cardiovascular disease 
(CVD) history (25.49%), 67 patients had fever 
(65.68%) and 21 patients (20.59%) had a degree of 
decline oxygen saturation. There were 75 patients 
(73.53%) with elevated hs-CRP, 58 patients (56.86%) 
with elevated serum creatinine, 33 patients (32.35%) 
with elevated cTnI, and 76 patients (74.51%) with 
anemia, 22 patients (21.56%) were mild and common 
confirmed COVID-19 cases, 2 cases (1.96%) 
developed to critical illness or death, 80 (78.43%) 
patients were severe and critical confirmed COVID-
19 cases, and 25 cases (24.51%) developed critical 
 
 
Fig. 1 — COVID-19 patients (102) with or without CKD but had 
kidney damage during hospitalization were included for statistical 
analysis 




illness or death. Among the medical interventions, 75 
patients (73.53%) got cured, however, 27 (26.47%) 
were developed critical illness or death, and 20 
(19.61%) of them died (Table 1). Furthermore, out of 
845 COVID-19 patients, a total of 36 (4.26%) 
developed AKI condition.  
 
Univariate logistic regression analysis of factors associated with 
COVID-19 patients who developed critical illness or death 
Univariate logistic regression analysis showed that 
decreased O2 saturation, elevated hs-CRP, elevated 
serum creatinine, elevated cTnI, and anemia were 
related factors for COVID-19 patients who developed 
critical illness or death (P <0.05). Specifically, the 
probability of COVID-19 patients with no decrease in 
O2 saturation developed critical illness or death was 
18.52%, and those with aerobic saturation decreased 
developed critical illness or death was 57.14%  
(P <0.001); COVID-19 patients with no elevated in 
hs-CRP had a probability of 3.70% who developed 
critical illness or death, and those with elevated in hs-
CRP had a probability of 34.67%, who developed to 
critical illness or death (P = 0.002). COVID-19 
patients with no elevated serum creatinine had a 
probability of 6.82% who developed critical illness or 
death, and those with elevated serum creatinine had a 
probability of 41.38% to develop to critical illness or 
death (P <0.001).  
Furthermore, COVID-19 patients with no elevated 
cTnI, had a probability of 8.70% to develop to critical 
illness or death, and those with elevated cTnI had a 
probability of 63.64% to develop to critical illness or 
death (P< 0.001). The COVID-19 patients without 
anemia had probability of 11.54% to develop critical 
illness or death, and those with anemia developed 
critical illness or death at rate of 31.58% (P = 0.046). 
Results of univariate logistic regression analysis are 
presented in Table 2. 
 
Multivariate logistic regression analysis of factors associated with 
COVID-19 patients who developed critical illness or death 
Factors with significant (P <0.05) outcomes in 
univariate analysis were further subjected to 
multivariate logistic regression analysis. The results 
showed that decreased O2 saturation, elevated hs-CRP 
and anemia were not independent factors for COVID-
19 patients who developed critical illness or death (P 
>0.05). However, elevated serum creatinine was 
independent factor development of critical illness or 
death (P = 0.040). Results suggested that the 
probability of developing critical illness or death 
among patients without elevated serum creatinine was 
22.2% and those with elevated serum creatinine 
included COVID-19 patients of kidney damage with 
or without CKD, which means that elevated serum 
creatinine is an independent risk factor for 
development of critical illness or death.  
Furthermore, elevated cTnI was also an 
independent factor that led to development of critical 
illness or death (P = 0.001). Probability of developing 
critical illness or death among patients without 
elevated cTnI was 12.1% as compared to patients with 






Developed critical illness 





Age [year，M (P25，P75)] 73.50 (65.75, 82.00) 73 (65`81) 77 (70`86) 1.897## 0.058 
Sex 
Male n (%) 61 (59.80) 42 (41.18) 19 (18.62) 1.705 0.192 
Female n (%) 41 (40.19) 33 (32.35) 8 (7.84) 
Length of hospital stay (days， ) 25.74±11.063 25.55±8.229 26.26±16.803 0.286
# 0.776 
Hypertension, n (%) 72 (70.59) 54 (52.94) 18 (17.65) 0.272 0.602 
Diabetes, n (%) 29 (28.43) 22 (21.57) 7 (6.86) 0.113 0.736 
Cardiovascular disease, n (%) 26 (25.49) 16 (15.69) 10 (9.80) 2.578 0.108 
Fever, n (%) 67 (65.68) 51 (50.00) 16 (15.68) 0.673 0.412 
Decreased oxygen saturation, n (%) 21 (20.59) 9 (8.82) 12 (11.77) 12.782* <0.001 
Elevated hs-CRP, n (%) 75 (73.53) 49 (48.04) 26 (25.49) 9.779* 0.002 
Elevated serum creatinine, n (%) 58 (56.86) 34 (33.33) 24 (23.53) 15.354* <0.001 
Elevated cTnI, n (%) 33 (32.35) 12 (11.76) 21 (20.59) 34.620* <0.001 
Anemia, n (%) 76 (74.51) 52 (50.98) 24 (23.53) 3.997* 0.046 
Clinical Classification, n (%) 
Mild 10 (9.80) 10 (9.80) 0 28.229* <0.001 
Moderate 12 (11.76) 10 (9.80) 2 (1.96) 
Severe 46 (45.10) 41 (40.20) 5 (4.90) 
Critical 34 (33.33) 14 (13.72) 20 (19.61) 
[*P <0.05; # data was conforms to normal distribution by SK normality test, ## data is non-normally distributed by SK normality test. hs- 
CRP: hypersensitive C-reactive protein, cTnI: cardiac troponin I] 
 




elevated cTnI COVID-19 patients with kidney 
damage but with or without CKD. Based on the above 
conclusions, the CKD or non-CKD COVID-19 
patients with kidney damage, the prediction accuracy 
is 73.5% if selected serum creatinine and cTnI were 
used to predict the outcome of the patients, indicating 
that the above conclusions have significant practice 
application value. Results of multivariate logistic 
regression analysis are presented in Table 3. 
The virus responsible for COVID-19 was named as 
Severe Acute Respiratory Syndrome Coronavirus 2 
(SARS-CoV-2) by World Health Organization 
(WHO) on February 11, 2020. The invasion of SARS-
CoV-2 into human cells is mainly mediated by 
cellular receptors angiotensin enzyme-2 (ACE2)
13
 and 
high expression of ACE2 in kidney suggests that it is 
the main target organ of SARS-CoV-2
14
. A number of 
studies have shown that patients with COVID-19 
infection had hematuria, proteinuria and elevated 
serum creatinine on admission were significantly 
associated with poor outcomes. Patients who 
developed AKI had a higher mortality risk as 
compared to patients without AKI
12,15
.  
This study shows that the probability of developing 
critical illness or death in patients without elevated 
serum creatinine was 22.2%, as compared to CKD or 
Table 2 — Univariate logistic regression analysis of factors associated with COVID-19 patients who developed critical illness or death 
Factors associated  
with COVID-19 
Outcome % who developed 




Cure Development of critical 
illness or death 
Sex Male 42 19 31.15 1.705 0.192 
Female 33 8 19.51 
Hypertension  
(yes vs. no) 
No 21 9 30.00 0.272 0.602 
Yes 54 18 25.00 
Diabetes  
(yes vs. no) 
No 53 20 27.40 0.113 0.736 
Yes 22 7 24.14 
Cardiovascular disease 
(yes vs. no) 
No 59 17 22.37 2.578 0.108 
Yes 16 10 38.46 
Fever  
(yes vs. no)  
No 24 11 31.43 0.673 0.412 
Yes 51 16 23.88 
Decreased oxygen 
saturation (yes vs. no) 
No 66 15 18.52 12.782* <0.001 
Yes 9 12 57.14 
Elevated hs-CRP  
(yes vs. no) 
No 26 1 3.70 9.779* 0.002 
Yes 49 26 34.67 
Elevated serum 
creatinine (yes vs. no) 
No 41 3 6.82 15.354* <0.001 
Yes 34 24 41.38 
Elevated cTnI  
(yes vs. no) 
No 63 6 8.70 34.620* <0.001 
Yes 12 21 63.64 
Anemia  
(yes vs. no) 
No 23 3 11.54 3.997* 0.046 
Yes 52 24 31.58 
Age## 73（65`81） 77（70`86）  1.897 0.058 
Length of hospital stay# 25.55±8.229 26.26±16.803  0.286 0.776 
[*P <0.05; # data was conforms to normal distribution by SK normality test, ## data is non-normally distributed by SK normality test. hs- 
CRP: hypersensitive C-reactive protein, cTnI: cardiac troponin I] 
 
Table 3—Multivariate logistic regression analysis of factors associated with COVID-19 patients who developed critical illness or death 








Significance OR 95% confidence interval for OR 
Lower limit Upper limit 
Decreased oxygen saturation 
(yes vs. no) 
no 0.746 0.707 1.116 1 0.291 0.474 0.119 1.894 
yes 0     1   
Elevated hs-CRP  
(yes vs. no) 
no 1.087 1.133 0.921 1 0.337 0.337 0.037 3.105 
yes 0     1   
Elevated serum creatinine  
(yes vs. no) 
no 1.505 0.734 4.204 1 0.040* 0.222 0.053 0.936 
yes 0     1   
Elevated cTnI  
(yes vs. no) 
no 2.113 0.632 11.183 1 0.001* 0.121 0.035 0.417 
yes 0     1   
Anemia  
(yes vs. no) 
no 0.725 0.867 0.700 1 0.403 0.484 0.089 2.647 
yes 0     1   
Constant 1.435 0.621 5.340 1 0.021 4.200   
[*P <0.05. hs CRP: hypersensitive C-reactive protein; cTnI: cardiac troponin I] 
 




non-CKD COVID-19 patients with elevated serum 
creatinine having kidney damage. This means that 
elevated serum creatinine is an independent risk factor 
of developing critical illness or death. Thus, the 
kidney damage is of great significance for the 
screening, prevention, condition judgment and 
prognosis of the COVID-19 epidemic. Hence, it is 
advisable that more attention be paid to the COVID-
19 patients with kidney damage when they are 
admitted to the hospitals. Kidney function must be 
closely monitored during the course of treatment and 
different measures of kidney protection be adopted 
according to the specific conditions of the COVID-19 
patients. 
AKI caused by coronavirus infection is not 
uncommon and the main manifestation is renal 
tubular injury. Studies indicated that the incidence of 
AKI was 6.7% in SARS-CoV and 75% in MERS-
CoV infection patients, respectively
16-18
. Our results 
showed 36 of 845 COVID-19 patients (4.26%) 
developed to AKI as compared to previous report that 
showed the rate of AKI ranged widely between 0.5 - 
29%. Such wide differences may be related to sample 
size and patient bias, and the overall incidence of AKI 
in COVID-19 patients seems to be lower than that in 
SARS and MERS cases. However, the exact 
incidence of AKI remains to be confirmed by larger 
sample data in the future. Continuous renal 
replacement therapy has been proved to be an 
effective in treatment of SARS-CoV in 2003 and 
MERS-CoV in 2012. SARS-CoV-2, like SARS-CoV 
and MERS-CoV, belongs to β-coronavirus
19
, which 
may have similarities in pathogenicity. Therefore, it 
can be speculated that if CRRT is used in time for 
progression of AKI among COVID-19 patients with 
kidney damage, the mortality rates might be 
significantly reduced. 
Reports suggest that the mortality of COVID-19 
patients with CVD and other risk factors is high
20,21
. 
Our results showed that elevated cTnI, a sensitive 
myocardial injury marker, was an independent risk 
factor of development of critical illness or death 
among CKD or non-CKD COVID-19 patients having 
kidney damage. However, COVID-19 patients with or 
without CVD is not a related factor of developing 
critical illness or death. Anincrease in cTnI is an 
important clinical feature of critical patients with 
COVID-19
22
. SARS-CoV-2 infection can cause 
cytokine storm syndrome (CSS), which has a series of 
effects on the cardiovascular system, and can promote 
thrombosis and myocardial infarction. At the same 
time, virus or inflammation itself can also directly 
lead to myocardial damage
23,24
. Therefore, the 
monitoring of cTnI is very important for condition 
assessment and prognosis judgment of patients with 
COVID-19. 
A study pointed out that the inflammation 
biomarkers in plasma samples of COVID-19 patients 
increased significantly, and the levels of related 
inflammatory factors in severe patients were 
significantly higher than those in mild patients
24
, which 
suggested that there is a correlation between cytokine 
storm and the severity of infection. In thisstudy, 63 
cases (61.76%) of severe and critical patients and 12 
cases (11.76%) of mild and common patients with 
elevated hs-CRP were found, which indicated that 
there was obvious inflammatory reaction among them, 
especially in the severe and critical cases. The results 
of univariate logistic regression analysis showed that 
the probability of developing critical illness or death 
was 3.70% in patients without increased hs-CRP, and 
34.67% in patients with increased hs-CRP (P = 0.002), 
and the difference was statistically significant. 
However, multivariate logistic regression analysis 
outcomes showed that the increase of hs-CRP was not 
an independent factor for developing critical illness or 
death, which needs further studies. It is suggested more 
attention be paid to adopt anti-infection and  




Our study found that the elevated serum creatinine 
and cTnI were more likely to develop critical illness 
or death in CKD or non- CKD COVID-19 patients 
having kidney damage and the two biomarkers can 
help in predicting the outcomes of such patients. 
Moreover, patients with CKD had a higher probability 
of developing critical illness or death after AKI, and 
the inflammatory storm reaction was more obvious in 
severe and critical cases. Therefore, it is suggested 
that more attention should be paid to early 
intervention of basic kidney disease, monitoring of 
cardiovascular related indicators and anti-
inflammatory treatment in COVID-19 patients in 
order to improve outcome and prognosis of the 
disease and reduce the mortality rate. 
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